Search research articles
Contact Us
Filters
Showing results (61-70 of 63) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Clinical and Translational Radiation Oncology
|
September 22, 2023
Patients' needs in proton therapy: A survey among ten European facilities
G C Mazzola, L Bergamaschi, C Pedone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D Azria, J Doyen, M Jarlier, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 63) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Clinical and Translational Radiation Oncology
|
September 22, 2023
Patients' needs in proton therapy: A survey among ten European facilities
G C Mazzola, L Bergamaschi, C Pedone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D Azria, J Doyen, M Jarlier, et al.
Page
of 7